Cholesterol metabolism modulation facilitates CAR-T induced killing of ovarian cancer

Chinmayee Vallabh Prabhu Dessai, Zhuoying Huang, Haonan Lin, Guangrui Ding, Hongjiang Wei, Menna Siddiqui, Meng Zhang, Wilson Wong, Ji-Xin ChengbioRxiv 2025 · DOI

TL;DR

Researchers have discovered that ovarian cancer cells that survive CAR-T therapy exhibit altered cholesterol metabolism, accumulating more cholesterol. By inhibiting this cholesterol esterification, they significantly enhanced CAR-T cell effectiveness against these tumors in both 2D and 3D models, offering a promising new strategy for treating this challenging cancer.

What Problem Does This Paper Address?

Ovarian cancer is a deadly disease with high recurrence rates, often due to resistance to existing treatments. While CAR-T cell therapy has shown great success in blood cancers, its application in solid tumors like ovarian cancer is limited. A key challenge is the tumor's ability to resist immune attack. This paper investigates the metabolic adaptations of ovarian cancer cells that allow them to survive CAR-T therapy, aiming to identify vulnerabilities that can be exploited to improve treatment efficacy. Specifically, they focus on how cancer cell metabolism influences their survival and interaction with CAR-T cells.

Methods

The study employs high-content stimulated Raman scattering (h²SRS) imaging, a label-free, non-destructive technique that provides high spatial resolution and can map multiple biomolecules simultaneously. They utilized both near-infrared (NIR) h²SRS and Visible h²SRS to analyze lipid metabolism in ovarian cancer cells. Visible h²SRS, with its improved resolution, was particularly useful for resolving individual lipid droplets.

Key techniques include:

  • Spectral unmixing using pixel-wise least absolute shrinkage and selection operator (LASSO) to decompose hyperspectral data into biochemical maps (e.g., for triglycerides, cholesterol, protein, nucleic acids).
  • Drug intervention using Avasimibe (inhibits cholesterol esterification) and Simvastatin (inhibits cholesterol synthesis) to modulate cholesterol metabolism.
  • Cell viability assays (MTS reagent) to assess drug toxicity.
  • Migration assays using trans-well membranes and confocal microscopy to evaluate cell movement.
  • Cytotoxicity assays in both 2D cell cultures and 3D tumor spheroids to measure CAR-T cell killing efficacy.
  • Confocal fluorescence imaging to visualize cell death and migration.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Survival fuels aggression: Ovarian cancer cells that survive CAR-T attack don't just survive; they adapt by increasing their cholesterol metabolism, leading to more lipid droplets and protrusions. This suggests a metabolic shift towards enhanced survival and potentially increased aggressiveness.
  • Cholesterol esterification is a key survival mechanism: The study pinpoints cholesterol esterification (specifically, the accumulation of cholesteryl esters and free cholesterol) as a critical metabolic adaptation for ovarian cancer cells to withstand CAR-T cell onslaught.
  • Targeting cholesterol esterification is more effective: Inhibiting cholesterol esterification with Avasimibe proved more potent in reducing cancer cell migration and enhancing CAR-T killing than inhibiting cholesterol synthesis with Simvastatin. This highlights a specific metabolic vulnerability.
  • Cytokines can have a dual role: While pro-inflammatory cytokines released by CAR-T cells are crucial for anti-tumor immunity, they can also paradoxically promote cancer cell aggressiveness and migration, partly by influencing lipid metabolism. TNF-α, in particular, showed a significant impact.

Key Results

  • Ovarian cancer cells surviving CAR-T treatment showed a 3.5-fold increase in triglycerides and a 2.3-fold increase in total cholesterol.
  • Visible h²SRS imaging revealed a 4.5-fold increase in free cholesterol (FC) and a 1.7-fold increase in cholesteryl ester (CE) in surviving cells.
  • Avasimibe treatment reduced SKOV3 cell migration by 95.5%, while Simvastatin reduced it by 47.4%.
  • Avasimibe pretreatment significantly enhanced CAR-T induced cytotoxicity in 2D cultures by ~10% (from 43.5% to 54.6%) and in 3D spheroids by ~2.5-fold (cytotoxicity index of 0.62 vs. 0.21).
  • Cytokine supplementation (IL-2, TNF-α, IFN-γ) also increased TAG and TC levels in SKOV3 cells, with TNF-α showing the most significant impact.
  • TNF-α treatment led to a nearly 100% increase in cell migration.

Limitations and Future Work

  • Spatial resolution limitations: While Visible h²SRS offers improved resolution, the study primarily focused on the C-H region, which might limit comprehensive metabolic profiling. Future work could explore the fingerprint region for broader metabolic insights.
  • Photodamage and penetration depth: SRS imaging can cause photodamage and has limited penetration depth, making it unsuitable for in vivo imaging of deep tissues. Alternative imaging modalities are suggested.
  • Cytokine complexity: The study highlights the complex, context-dependent roles of cytokines in cancer progression and immune response. Further research is needed to fully understand these interactions and their implications for CAR-T therapy.
  • In vivo validation: While promising results were shown in 2D and 3D models, future work should focus on validating these findings and therapeutic strategies in in vivo animal models.
  • Broader metabolic pathways: The study focused on cholesterol metabolism. Exploring other metabolic pathways and their interplay with CAR-T therapy could reveal additional therapeutic targets.

Summary updated

Abstract

Ovarian cancer is a major global health challenge, mainly due to relapse driven by chemotherapy resistance development. Meanwhile, immunotherapies such as CAR-T have revolutionized treatment for blood cancers, but their application in solid tumors like ovarian cancer is hindered by limited efficacy. This study uses high-content stimulated Raman scattering (SRS) imaging to reveal metabolic adaptations that help ovarian cancer cells survive CAR-T-mediated cytotoxicity. Guided by these insights, we apply metabolic interventions that enhance CAR-T cytotoxicity efficacy. This approach reveals therapeutic vulnerabilities in ovarian cancer and demonstrates an investigative strategy applicable for overcoming resistance in solid tumors.
BibTeX
@misc{dessai2025cholesterol,
  author = {Chinmayee Vallabh Prabhu Dessai and Zhuoying Huang and Haonan Lin and Guangrui Ding and Hongjiang Wei and Menna Siddiqui and Meng Zhang and Wilson Wong and Ji-Xin Cheng},
  title = {{Cholesterol metabolism modulation facilitates CAR-T induced killing of ovarian cancer}},
  year = {2025},
  doi = {10.1101/2025.08.20.671345},
  howpublished = {bioRxiv},
}
Figure